1
|
Hocine S, Duchamp E, Mishra A, Fourquez JM, Hanessian S. Synthesis of Aza-Bridged Perhydroazulene Chimeras of Tropanes and Hederacine A. J Org Chem 2023; 88:4675-4686. [PMID: 36940388 DOI: 10.1021/acs.joc.3c00169] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/22/2023]
Abstract
We report the synthesis of two novel azaperhydroazulene tropane-hederacine chimeras A and B, which contain an 8-azabicyclo[3.2.1]octane ring and a 7-azabicyclo[4.1.1]octane ring, respectively. The synthesis of both chimeras was achieved by epoxide ring opening and was governed by the stereochemistry of the hydroxy-epoxide unit. Finally, a density functional theory study was conducted to explain the regioselectivity of the cyclization and the importance of the stereochemistry of the hydroxyl group.
Collapse
Affiliation(s)
- Sofiane Hocine
- Department of Chemistry, Université de Montréal, Station Centre-Ville, C.P. 6128, Montreal, Quebec H3C 3J7, Canada
| | - Edouard Duchamp
- Department of Chemistry, Université de Montréal, Station Centre-Ville, C.P. 6128, Montreal, Quebec H3C 3J7, Canada
| | - Akash Mishra
- Department of Chemistry, Université de Montréal, Station Centre-Ville, C.P. 6128, Montreal, Quebec H3C 3J7, Canada
| | | | - Stephen Hanessian
- Department of Chemistry, Université de Montréal, Station Centre-Ville, C.P. 6128, Montreal, Quebec H3C 3J7, Canada
| |
Collapse
|
2
|
Dalavai R, Gomathi K, Naresh K, Nawaz Khan FR. One-Pot Synthesis of Quinolinyl Amino Nitriles and Their Antidiabetic, Anti-inflammatory, Antioxidant, and Molecular Docking Studies. Polycycl Aromat Compd 2020. [DOI: 10.1080/10406638.2020.1791917] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Affiliation(s)
- Ramesh Dalavai
- Organic and Medicinal Chemistry Laboratory, Vellore Institute of Technology, Vellore, Tamil Nadu, India
| | - Kannayiram Gomathi
- Department of Biotechnology, Dr. MGR Educational Research Institute, Chennai Tamil Nadu, India
| | - K. Naresh
- Department of Pharmaceutical and Medicinal Chemistry, G. Pulla Reddy College of Pharmacy, Hyderabad, Telangana, India
| | - Fazlur-Rahman Nawaz Khan
- Organic and Medicinal Chemistry Laboratory, Vellore Institute of Technology, Vellore, Tamil Nadu, India
| |
Collapse
|
3
|
Ladraa S, Chioua M, Belfaitah A. A Simple and Ecofriendly One-Pot Synthesis of Highly Substituted 3-Cyanopyridine-Quinoline Hybridsviaa Triphenyphosphine-Catalyzed Multicomponent Reaction Under Mild Conditions. J Heterocycl Chem 2016. [DOI: 10.1002/jhet.2631] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- Souheila Ladraa
- Laboratoire des Produits Naturels d'Origine Végétale et de Synthèse Organique, Faculté des Sciences Exactes, Campus de Chaabat Ersas; Université des frères Mentouri-Constantine; Constantine 25000 Algeria
| | - Mourad Chioua
- Instituto de Quimica Organica General; Spanish National Research Council; CSIC at C/Serrano, 117 28006 Madrid Spain
| | - Ali Belfaitah
- Laboratoire des Produits Naturels d'Origine Végétale et de Synthèse Organique, Faculté des Sciences Exactes, Campus de Chaabat Ersas; Université des frères Mentouri-Constantine; Constantine 25000 Algeria
| |
Collapse
|
4
|
Letavic MA, Aluisio L, Apodaca R, Bajpai M, Barbier AJ, Bonneville A, Bonaventure P, Carruthers NI, Dugovic C, Fraser IC, Kramer ML, Lord B, Lovenberg TW, Li LY, Ly KS, Mcallister H, Mani NS, Morton KL, Ndifor A, Nepomuceno SD, Pandit CR, Sands SB, Shah CR, Shelton JE, Snook SS, Swanson DM, Xiao W. Novel benzamide-based histamine h3 receptor antagonists: the identification of two candidates for clinical development. ACS Med Chem Lett 2015; 6:450-4. [PMID: 25893048 DOI: 10.1021/ml5005156] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2014] [Accepted: 03/13/2015] [Indexed: 11/29/2022] Open
Abstract
The preclinical characterization of novel phenyl(piperazin-1-yl)methanones that are histamine H3 receptor antagonists is described. The compounds described are high affinity histamine H3 antagonists. Optimization of the physical properties of these histamine H3 antagonists led to the discovery of several promising lead compounds, and extensive preclinical profiling aided in the identification of compounds with optimal duration of action for wake promoting activity. This led to the discovery of two development candidates for Phase I and Phase II clinical trials.
Collapse
Affiliation(s)
- Michael A. Letavic
- Janssen Pharmaceutical Company, a division of Johnson & Johnson Pharmaceutical Research & Development L.L.C., 3210 Merryfield Row, San Diego, California 92121, United States
| | - Leah Aluisio
- Janssen Pharmaceutical Company, a division of Johnson & Johnson Pharmaceutical Research & Development L.L.C., 3210 Merryfield Row, San Diego, California 92121, United States
| | - Richard Apodaca
- Janssen Pharmaceutical Company, a division of Johnson & Johnson Pharmaceutical Research & Development L.L.C., 3210 Merryfield Row, San Diego, California 92121, United States
| | - Manoj Bajpai
- Janssen Pharmaceutical Company, a division of Johnson & Johnson Pharmaceutical Research & Development L.L.C., 3210 Merryfield Row, San Diego, California 92121, United States
| | - Ann J. Barbier
- Janssen Pharmaceutical Company, a division of Johnson & Johnson Pharmaceutical Research & Development L.L.C., 3210 Merryfield Row, San Diego, California 92121, United States
| | - Anne Bonneville
- Janssen Pharmaceutical Company, a division of Johnson & Johnson Pharmaceutical Research & Development L.L.C., 3210 Merryfield Row, San Diego, California 92121, United States
| | - Pascal Bonaventure
- Janssen Pharmaceutical Company, a division of Johnson & Johnson Pharmaceutical Research & Development L.L.C., 3210 Merryfield Row, San Diego, California 92121, United States
| | - Nicholas I. Carruthers
- Janssen Pharmaceutical Company, a division of Johnson & Johnson Pharmaceutical Research & Development L.L.C., 3210 Merryfield Row, San Diego, California 92121, United States
| | - Christine Dugovic
- Janssen Pharmaceutical Company, a division of Johnson & Johnson Pharmaceutical Research & Development L.L.C., 3210 Merryfield Row, San Diego, California 92121, United States
| | - Ian C. Fraser
- Janssen Pharmaceutical Company, a division of Johnson & Johnson Pharmaceutical Research & Development L.L.C., 3210 Merryfield Row, San Diego, California 92121, United States
| | - Michelle L. Kramer
- Janssen Pharmaceutical Company, a division of Johnson & Johnson Pharmaceutical Research & Development L.L.C., 3210 Merryfield Row, San Diego, California 92121, United States
| | - Brian Lord
- Janssen Pharmaceutical Company, a division of Johnson & Johnson Pharmaceutical Research & Development L.L.C., 3210 Merryfield Row, San Diego, California 92121, United States
| | - Timothy W. Lovenberg
- Janssen Pharmaceutical Company, a division of Johnson & Johnson Pharmaceutical Research & Development L.L.C., 3210 Merryfield Row, San Diego, California 92121, United States
| | - Lilian Y. Li
- Janssen Pharmaceutical Company, a division of Johnson & Johnson Pharmaceutical Research & Development L.L.C., 3210 Merryfield Row, San Diego, California 92121, United States
| | - Kiev S. Ly
- Janssen Pharmaceutical Company, a division of Johnson & Johnson Pharmaceutical Research & Development L.L.C., 3210 Merryfield Row, San Diego, California 92121, United States
| | - Heather Mcallister
- Janssen Pharmaceutical Company, a division of Johnson & Johnson Pharmaceutical Research & Development L.L.C., 3210 Merryfield Row, San Diego, California 92121, United States
| | - Neelakandha S. Mani
- Janssen Pharmaceutical Company, a division of Johnson & Johnson Pharmaceutical Research & Development L.L.C., 3210 Merryfield Row, San Diego, California 92121, United States
| | - Kirsten L. Morton
- Janssen Pharmaceutical Company, a division of Johnson & Johnson Pharmaceutical Research & Development L.L.C., 3210 Merryfield Row, San Diego, California 92121, United States
| | - Anthony Ndifor
- Janssen Pharmaceutical Company, a division of Johnson & Johnson Pharmaceutical Research & Development L.L.C., 3210 Merryfield Row, San Diego, California 92121, United States
| | - S. Diane Nepomuceno
- Janssen Pharmaceutical Company, a division of Johnson & Johnson Pharmaceutical Research & Development L.L.C., 3210 Merryfield Row, San Diego, California 92121, United States
| | - Chennagiri R. Pandit
- Janssen Pharmaceutical Company, a division of Johnson & Johnson Pharmaceutical Research & Development L.L.C., 3210 Merryfield Row, San Diego, California 92121, United States
| | - Steven B. Sands
- Janssen Pharmaceutical Company, a division of Johnson & Johnson Pharmaceutical Research & Development L.L.C., 3210 Merryfield Row, San Diego, California 92121, United States
| | - Chandra R. Shah
- Janssen Pharmaceutical Company, a division of Johnson & Johnson Pharmaceutical Research & Development L.L.C., 3210 Merryfield Row, San Diego, California 92121, United States
| | - Jonathan E. Shelton
- Janssen Pharmaceutical Company, a division of Johnson & Johnson Pharmaceutical Research & Development L.L.C., 3210 Merryfield Row, San Diego, California 92121, United States
| | - Sandra S. Snook
- Janssen Pharmaceutical Company, a division of Johnson & Johnson Pharmaceutical Research & Development L.L.C., 3210 Merryfield Row, San Diego, California 92121, United States
| | - Devin M. Swanson
- Janssen Pharmaceutical Company, a division of Johnson & Johnson Pharmaceutical Research & Development L.L.C., 3210 Merryfield Row, San Diego, California 92121, United States
| | - Wei Xiao
- Janssen Pharmaceutical Company, a division of Johnson & Johnson Pharmaceutical Research & Development L.L.C., 3210 Merryfield Row, San Diego, California 92121, United States
| |
Collapse
|
5
|
Drug-Induced Phospholipidosis: Prediction, Detection, and Mitigation Strategies. ACTA ACUST UNITED AC 2014. [DOI: 10.1007/7355_2013_34] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/20/2023]
|
6
|
Gao Z, Hurst WJ, Czechtizky W, Hall D, Moindrot N, Nagorny R, Pichat P, Stefany D, Hendrix JA, George PG. Identification and profiling of 3,5-dimethyl-isoxazole-4-carboxylic acid [2-methyl-4-((2S,3′S)-2-methyl-[1,3′]bipyrrolidinyl-1′-yl)phenyl] amide as histamine H3 receptor antagonist for the treatment of depression. Bioorg Med Chem Lett 2013; 23:6269-73. [DOI: 10.1016/j.bmcl.2013.09.081] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2013] [Revised: 09/24/2013] [Accepted: 09/25/2013] [Indexed: 01/08/2023]
|
7
|
Discovery of a potent, selective, and orally bioavailable histamine H3 receptor antagonist SAR110068 for the treatment of sleep–wake disorders. Bioorg Med Chem Lett 2013; 23:6141-5. [DOI: 10.1016/j.bmcl.2013.09.006] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2013] [Revised: 08/30/2013] [Accepted: 09/03/2013] [Indexed: 01/06/2023]
|
8
|
Łażewska D, Kieć-Kononowicz K. New developments around histamine H3receptor antagonists/inverse agonists: a patent review (2010 – present). Expert Opin Ther Pat 2013; 24:89-111. [DOI: 10.1517/13543776.2014.848197] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
9
|
Ladraa S, Berrée F, Bouraiou A, Bouacida S, Roisnel T, Carboni B, Belfaitah A. Efficient synthesis and X-ray structures of new α-quinolin-3-yl-α-aminonitriles and derivatives. Tetrahedron Lett 2013. [DOI: 10.1016/j.tetlet.2012.11.032] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
|
10
|
Sun H, Shahane S, Xia M, Austin CP, Huang R. Structure based model for the prediction of phospholipidosis induction potential of small molecules. J Chem Inf Model 2012; 52:1798-805. [PMID: 22725677 PMCID: PMC3484221 DOI: 10.1021/ci3001875] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Drug-induced phospholipidosis (PLD), characterized by an intracellular accumulation of phospholipids and formation of concentric lamellar bodies, has raised concerns in the drug discovery community, due to its potential adverse effects. To evaluate the PLD induction potential, 4,161 nonredundant drug-like molecules from the National Institutes of Health Chemical Genomics Center (NCGC) Pharmaceutical Collection (NPC), the Library of Pharmacologically Active Compounds (LOPAC), and the Tocris Biosciences collection were screened in a quantitative high-throughput screening (qHTS) format. The potential of drug-lipid complex formation can be linked directly to the structures of drug molecules, and many PLD inducing drugs were found to share common structural features. Support vector machine (SVM) models were constructed by using customized atom types or Molecular Operating Environment (MOE) 2D descriptors as structural descriptors. Either the compounds from LOPAC or randomly selected from the entire data set were used as the training set. The impact of training data with biased structural features and the impact of molecule descriptors emphasizing whole-molecule properties or detailed functional groups at the atom level on model performance were analyzed and discussed. Rebalancing strategies were applied to improve the predictive power of the SVM models. Using the undersampling method, the consensus model using one-third of the compounds randomly selected from the data set as the training set achieved high accuracy of 0.90 in predicting the remaining two-thirds of the compounds constituting the test set, as measured by the area under the receiver operator characteristic curve (AUC-ROC).
Collapse
Affiliation(s)
- Hongmao Sun
- National Institutes of Health (NIH) Chemical Genomics Center, NIH, Bethesda, Maryland 20892, United States.
| | | | | | | | | |
Collapse
|
11
|
Fischer H, Atzpodien EA, Csato M, Doessegger L, Lenz B, Schmitt G, Singer T. In Silico Assay for Assessing Phospholipidosis Potential of Small Druglike Molecules: Training, Validation, and Refinement Using Several Data Sets. J Med Chem 2012; 55:126-39. [DOI: 10.1021/jm201082a] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Holger Fischer
- Clinical
Safety/Licensing and Early Development, ‡Toxicology and Pathology, §Early and Investigative
Safety, Non-Clinical Safety, and ∥Non-Clinical Safety, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland
| | - Elke-Astrid Atzpodien
- Clinical
Safety/Licensing and Early Development, ‡Toxicology and Pathology, §Early and Investigative
Safety, Non-Clinical Safety, and ∥Non-Clinical Safety, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland
| | - Miklos Csato
- Clinical
Safety/Licensing and Early Development, ‡Toxicology and Pathology, §Early and Investigative
Safety, Non-Clinical Safety, and ∥Non-Clinical Safety, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland
| | - Lucette Doessegger
- Clinical
Safety/Licensing and Early Development, ‡Toxicology and Pathology, §Early and Investigative
Safety, Non-Clinical Safety, and ∥Non-Clinical Safety, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland
| | - Barbara Lenz
- Clinical
Safety/Licensing and Early Development, ‡Toxicology and Pathology, §Early and Investigative
Safety, Non-Clinical Safety, and ∥Non-Clinical Safety, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland
| | - Georg Schmitt
- Clinical
Safety/Licensing and Early Development, ‡Toxicology and Pathology, §Early and Investigative
Safety, Non-Clinical Safety, and ∥Non-Clinical Safety, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland
| | - Thomas Singer
- Clinical
Safety/Licensing and Early Development, ‡Toxicology and Pathology, §Early and Investigative
Safety, Non-Clinical Safety, and ∥Non-Clinical Safety, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland
| |
Collapse
|
12
|
Synthesis and X-ray structures of new cycloalka[e]pyrano[2,3-b]pyridine derivatives: novel tacrine analogues. Tetrahedron Lett 2011. [DOI: 10.1016/j.tetlet.2011.07.038] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
13
|
Michel BW, Steffens LD, Sigman MS. On the mechanism of the palladium-catalyzed tert-butylhydroperoxide-mediated Wacker-type oxidation of alkenes using quinoline-2-oxazoline ligands. J Am Chem Soc 2011; 133:8317-25. [PMID: 21553838 DOI: 10.1021/ja2017043] [Citation(s) in RCA: 86] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
The mechanism of the tert-butylhydroperoxide-mediated, Pd(Quinox)-catalyzed Wacker-type oxidation was investigated to evaluate the hypothesis that a selective catalyst-controlled oxidation could be achieved by rendering the palladium coordinatively saturated using a bidentate amine ligand. The unique role of the Quinox ligand framework was probed via systematic ligand modifications. The modified ligands were evaluated through quantitative Hammett analysis, which supports a "push-pull" relationship between the electronically asymmetric quinoline and oxazoline ligand modules.
Collapse
Affiliation(s)
- Brian W Michel
- Department of Chemistry, University of Utah, 315 South 1400 East, Salt Lake City, Utah 84112, USA
| | | | | |
Collapse
|
14
|
Kanagarajan V, Thanusu J, Gopalakrishnan M. Synthesis, spectral analysis and in vitro microbiological evaluation of novel ethyl 4-(naphthalen-2-yl)-2-oxo-6-arylcyclohex-3-enecarboxylates and 4,5-dihydro-6-(napthalen-2-yl)-4-aryl-2H-indazol-3-ols. J Enzyme Inhib Med Chem 2011; 26:56-66. [DOI: 10.3109/14756361003689856] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- V. Kanagarajan
- Synthetic Organic Chemistry Laboratory, Department of Chemistry, Annamalai University, Annamalainagar, Tamil Nadu, India
| | - J. Thanusu
- Synthetic Organic Chemistry Laboratory, Department of Chemistry, Annamalai University, Annamalainagar, Tamil Nadu, India
| | - M. Gopalakrishnan
- Synthetic Organic Chemistry Laboratory, Department of Chemistry, Annamalai University, Annamalainagar, Tamil Nadu, India
| |
Collapse
|
15
|
Bernstein PR, Ciaccio P, Morelli J. Drug-Induced Phospholipidosis. ANNUAL REPORTS IN MEDICINAL CHEMISTRY 2011. [DOI: 10.1016/b978-0-12-386009-5.00001-1] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
|
16
|
Łażewska D, Kieć-Kononowicz K. Recent advances in histamine H3receptor antagonists/inverse agonists. Expert Opin Ther Pat 2010; 20:1147-69. [DOI: 10.1517/13543776.2010.509346] [Citation(s) in RCA: 50] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
17
|
Strasser A. Molecular modeling and QSAR-based design of histamine receptor ligands. Expert Opin Drug Discov 2009; 4:1061-75. [DOI: 10.1517/17460440903264972] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|